

2014 Research Annual Report

Center for Technology Commercialization



Significant Accomplishments

Rare Disease Collaborative Launched with Alexion Pharmaceuticals

Cincinnati Children's and Alexion Pharmaceuticals have established a collaboration and fund for the advancement of research in rare diseases. The Alexion Rare Disease Innovation Fund is a focused opportunity within Cincinnati Children's broader Innovation Fund, which covers all therapeutic areas and technology types. The program, open to all Cincinnati Children's researchers, will focus on research that aligns with Alexion's specialty of developing new treatments for complex and rare diseases. The Center for Technology Commercialization (CTC) believes this type of collaboration will serve as a model for how industry and academia can better work together to bring health innovations from the bench to the bedside.

Commercialization-Related Revenue Up 30 Percent

The CTC generated more than \$6.2 million in commercialization-related revenue and funds this year from a variety of sources, up approximately 30 percent over the previous year. Revenue from the CTC's licensing activity totaled roughly \$1.2 million, with industry-sponsored research totaling \$1.5 million. Approximately \$500,000 was received for patent reimbursement from current licensees and \$3 million was received in commercialization grants. The significant grant funding came from Ohio's Third Frontier for Cincinnati Children's start-up fund, which will be matched by the medical center for a total of \$6 million for Cincinnati Children's new start-ups.

New Start-Up Formed, Existing Start-Ups Hit Major Milestones

Persepsys Biomedical LLC, a new Cincinnati Children's start-up, launched this year based on research and technology from the lab of **Hector Wong, MD**, director, Critical Care Medicine. The company, still in an early stage, hopes to offer products that will help with the management and prognosis of severe sepsis and septic shock. They also see strong opportunities to use the technology as a diagnostic and quality outcomes tool.

Several other start-ups have achieved major milestones: Assurex Health was named an approved supplier to the US. Department of Veterans Affairs and will soon offer their GeneSight psychotropic test to help doctors prescribe the best medications to treat patients with mental issues. Airway Therapeutics, working to help premature babies avoid developing bronchopulmonary dysplasia (BPD), was granted orphan designation by the US Food and Drug Administration. Bexion Pharmaceuticals, focused on cancer therapeutics, recently submitted an Investigational New Drug (IND) application to the FDA in support of its upcoming Phase 1 clinical trial.